Alector is a preclinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Lewy body dementia. Its programs aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Every program in its current pipeline is built on the proprietary Alector Brain Carrier (ABC), a blood-brain barrier platform that binds a distinct region of the transferrin receptor. ABC is designed to increase brain delivery of antibodies, enzymes, proteins and siRNA through peripheral (subcutaneous) dosing.
The lead program is AL137, an ABC-enabled anti-pyroglutamate-3 amyloid beta antibody for Alzheimer's disease designed for monthly subcutaneous administration. It is targeting first-in-human dosing in Australia no later than April 2027. Siliconcandidates in the siRNA portfolio include:
- AL164 (tau), for Alzheimer's disease and other tauopathies
- AL062 (alpha-synuclein), for Parkinson's disease and Lewy body dementia
- ADP065 (NLRP3), an earlier-stage program
AL164 and AL062 are targeting first-in-human studies in Q2 2028.
Alector earns collaboration and licensing revenue. It exclusively licensed its AL050 GCase enzyme replacement therapy to Genentech in exchange for a $100 million upfront payment, up to $1.17 billion in milestones and royalties. Its former GSK collaboration was terminated in July 2026. The company has wound down its earlier clinical programs, latozinemab and nivisnebart. Updated
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each. Hims & Hers Health (NYSE:HIMS) received two separate upgrades after…
Alector is a preclinical-stage biotechnology company developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Lewy body dementia. Its programs aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function.